Close Menu
Home › Cigna to Cover Interpace ThyGenX Thyroid MDx

Cigna to Cover Interpace ThyGenX Thyroid MDx

Jul 27, 2017
|
staff reporter

NEW YORK (GenomeWeb) – Interpace Diagnostics said today that its ThyGenX molecular thyroid test will now be covered by Cigna.

The test uses next-generation sequencing to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, and is designed to assess fine needle aspiration samples from indeterminate thyroid nodules.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
16
Featured Webinar

Using Next-Generation Sequencing to Detect Genomic Mutations in Hematologic Malignancies

Sponsored by
ArcherDX

This webinar will discuss a next-generation sequencing approach for detecting genomic mutations in hematologic maglignancies.

Oct
24
Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

What's Popular?

In Molecular Diagnostics

  1. FDA Stepping Up Actions Against PGx Testing, Forcing Some Labs to Stop Reporting Drug Information

  2. Genomind, NeuroFlow Collaborate to Provide Genetic Testing-Based Mental Health Services

  3. Complex Genetic Testing Errors Emerge Amid Increasing Panel Use, Consumer Access, Case Series Finds

    Premium

  4. Canaccord Genuity, SVB Leerink Initiate Coverage of Castle Biosciences

  5. Inflammatix Preps Immune-Response Sepsis Dx for FDA Clinical Trial, Lays Out Future Test Plans

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.